{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PTCL&page=2", "query": { "condition": "PTCL", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PTCL&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T15:23:13.610Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00481871", "title": "Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Lymphoproliferative Malignancies", "Hodgkin's Lymphoma", "Peripheral T-cell Lymphoma", "B-cell Lymphoma", "Waldenstrom's Macroglobulinemia" ], "interventions": [ { "name": "Pralatrexate Injection", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Vitamin B12", "type": "DIETARY_SUPPLEMENT" }, { "name": "Folic Acid", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Acrotech Biopharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2007-05", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2020-01-07", "last_synced_at": "2026-07-22T15:23:13.610Z", "location_count": 15, "location_summary": "Los Angeles, California • Stanford, California • Denver, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00481871" }, { "nct_id": "NCT05403450", "title": "A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "Tolinapant", "type": "DRUG" }, { "name": "Decitabine + Cedazuridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2023-02-22", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-07-22T15:23:13.610Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • Stanford, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05403450" }, { "nct_id": "NCT00888927", "title": "Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "KW-0761", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2009-05", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-07-22T15:23:13.610Z", "location_count": 5, "location_summary": "Los Angeles, California • Stanford, California • New Haven, Connecticut + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00888927" }, { "nct_id": "NCT04569032", "title": "A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2020-11-12", "completion_date": "2026-01-12", "has_results": true, "last_update_posted_date": "2026-02-18", "last_synced_at": "2026-07-22T15:23:13.610Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Stanford, California • Aurora, Colorado + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04569032" }, { "nct_id": "NCT04072458", "title": "A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mantle Cell Lymphoma", "Peripheral T-cell Lymphoma (PTCL)", "Cutaneous T-cell Lymphoma (CTCL)", "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Hodgkin Lymphoma", "Waldenstrom Macroglobulinemia", "DLBCL" ], "interventions": [ { "name": "L-Bcl-2 antisense oligonucleotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bio-Path Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-11-05", "completion_date": "2025-04", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-07-22T15:23:13.610Z", "location_count": 5, "location_summary": "Augusta, Georgia • Valhalla, New York • Nashville, Tennessee + 2 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Valhalla", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04072458" }, { "nct_id": "NCT07055477", "title": "A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed and/or Refractory Mature T Cell Malignancy", "Peripheral T-Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Hepatosplenic T-cell Lymphoma", "Monomorphic Epithelialtropic Intestinal Lymphoma", "Enteropathy Associated T-cell Lymphoma", "Cutaneous T-Cell Lymphoma", "Mycosis Fungoides", "Subacute Panniculitis-like T-cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Autologous CCR4 CAR T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 60, "start_date": "2025-09-29", "completion_date": "2044-06-01", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-07-22T15:23:13.610Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07055477" }, { "nct_id": "NCT02732275", "title": "DS-3201b in Participants With Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Malignant", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "DS-3201b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2016-03-31", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-07-22T15:23:13.610Z", "location_count": 10, "location_summary": "Duarte, California • New Haven, Connecticut • Atlanta, Georgia + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02732275" }, { "nct_id": "NCT02512497", "title": "Romidepsin Maintenance After Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous T-cell Lymphoma", "T-Prolymphocytic Leukemia", "T-Large Granulocytic Leukemia", "T-Lymphoblastic Leukemia/Lymphoma", "Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "Thymoglobulin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 23, "start_date": "2017-12-08", "completion_date": "2025-06-18", "has_results": false, "last_update_posted_date": "2025-09-19", "last_synced_at": "2026-07-22T15:23:13.610Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02512497" }, { "nct_id": "NCT01142674", "title": "T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma, T-Cell, Peripheral" ], "interventions": [], "intervention_types": [], "sponsor": "Associazione Angela Serra per la ricerca sul cancro", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1650, "start_date": "2006-09", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2019-07-08", "last_synced_at": "2026-07-22T15:23:13.610Z", "location_count": 8, "location_summary": "Palo Alto, California • New Haven, Connecticut • St Louis, Missouri + 5 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01142674" }, { "nct_id": "NCT05274997", "title": "A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T/NK Cell Lymphoma (R/R PTCL)" ], "interventions": [ { "name": "YY-20394", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai YingLi Pharmaceutical Co. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2022-05-01", "completion_date": "2023-12-01", "has_results": false, "last_update_posted_date": "2022-10-21", "last_synced_at": "2026-07-22T15:23:13.610Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05274997" } ] }